Aquestive Therapeutics Stock Forecast, Price & News

-0.15 (-3.38 %)
(As of 06/24/2021 02:24 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume34,834 shs
Average Volume786,459 shs
Market Capitalization$156.98 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aquestive Therapeutics logo

About Aquestive Therapeutics

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.51 out of 5 stars

Medical Sector

596th out of 2,105 stocks

Pharmaceutical Preparations Industry

289th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

Is Aquestive Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aquestive Therapeutics stock.
View analyst ratings for Aquestive Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aquestive Therapeutics?

Wall Street analysts have given Aquestive Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aquestive Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Aquestive Therapeutics

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings results on Monday, May, 3rd. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.02. The company had revenue of $11.12 million for the quarter, compared to analyst estimates of $9.15 million.
View Aquestive Therapeutics' earnings history

How has Aquestive Therapeutics' stock price been impacted by COVID-19?

Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AQST stock has increased by 47.3% and is now trading at $4.33.
View which stocks have been most impacted by COVID-19

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $38 million-$42 million, compared to the consensus revenue estimate of $39.13 million.

What price target have analysts set for AQST?

5 brokers have issued 12 month price targets for Aquestive Therapeutics' shares. Their forecasts range from $7.00 to $30.00. On average, they expect Aquestive Therapeutics' stock price to reach $14.67 in the next year. This suggests a possible upside of 238.7% from the stock's current price.
View analysts' price targets for Aquestive Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the following people:
  • Mr. Keith J. Kendall, CEO, Pres & Director (Age 63, Pay $1.03M)
  • Mr. Daniel Barber, Sr. VP & COO (Age 45, Pay $713.28k)
  • Mr. Ernie Toth, Sr. VP & CFO (Age 62)
  • Mr. Alexander Mark Schobel, Chief Innovation & Technology Officer (Age 62)
  • Ms. Lori J. Braender Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 65)
  • Mr. Lauren Walrath, Head of Corp. Marketing & Communications
  • Ms. Theresa Wood, Sr. VP of HR & Organizational Devel. (Age 58)
  • Dr. Eric Dadey Ph.D., Sr. Vice-Pres of R&D
  • Mr. Peter E. Boyd, Sr. VP of Bus. Process & Information Technology (Age 55)
  • Mr. Kenneth W. Marshall, Sr. VP & Chief Commercial Officer (Age 62)

Who are some of Aquestive Therapeutics' key competitors?

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), OrganiGram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.71%), Nuveen Asset Management LLC (2.09%), Morgan Stanley (0.98%), Geode Capital Management LLC (0.97%), Northern Trust Corp (0.58%) and GSA Capital Partners LLP (0.57%). Company insiders that own Aquestive Therapeutics stock include Alexander Mark Schobel, Daniel Barber, James S Scibetta, John T Maxwell, Keith J Kendall, Lori J Braender, Peter E Boyd and Theresa Wood.
View institutional ownership trends for Aquestive Therapeutics

Which major investors are selling Aquestive Therapeutics stock?

AQST stock was sold by a variety of institutional investors in the last quarter, including Oak Grove Capital LLC, Jane Street Group LLC, Northern Trust Corp, UBS Group AG, Massachusetts Financial Services Co. MA, and Goldman Sachs Group Inc.. Company insiders that have sold Aquestive Therapeutics company stock in the last year include Alexander Mark Schobel, and John T Maxwell.
View insider buying and selling activity for Aquestive Therapeutics
or view top insider-selling stocks.

Which major investors are buying Aquestive Therapeutics stock?

AQST stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Nuveen Asset Management LLC, GSA Capital Partners LLP, IndexIQ Advisors LLC, Bank of New York Mellon Corp, HighTower Advisors LLC, BlackRock Inc., and Geode Capital Management LLC. Company insiders that have bought Aquestive Therapeutics stock in the last two years include Daniel Barber, James S Scibetta, Keith J Kendall, Lori J Braender, Peter E Boyd, and Theresa Wood.
View insider buying and selling activity for Aquestive Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $4.33.

How much money does Aquestive Therapeutics make?

Aquestive Therapeutics has a market capitalization of $158.44 million and generates $45.85 million in revenue each year. The company earns $-55,780,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How many employees does Aquestive Therapeutics have?

Aquestive Therapeutics employs 187 workers across the globe.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is

Where are Aquestive Therapeutics' headquarters?

Aquestive Therapeutics is headquartered at 30 TECHNOLOGY DRIVE, WARREN NJ, 07059.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at 908-941-1900 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.